REGN · XBRL financial data

Regeneron Pharmaceuticals financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (REGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	8,497	16,072	12,173	13,117	14,202	14,343
Research and development	2,735	2,908	3,593	4,439	5,132	5,850
Selling, general and administrative	1,346	1,825	2,116	2,631	2,954	2,700
Other operating income (expense)	280	46	90	2	(53)	10
Operating income (loss)	3,577	8,947	4,739	4,047	3,991	3,578
Interest expense	57	57	59	73	55	44
Other income (expense)	291	436	179	225	844	1,697
Income tax expense (benefit)	297	1,251	520	246	367	726
Net income (loss)	3,513	8,075	4,338	3,954	4,413	4,505
Earnings per share, basic USD per share	32.65	76.40	40.51	37.05	40.90	43.07
Earnings per share, diluted USD per share	30.52	71.97	38.22	34.77	38.34	41.48
Weighted average shares, basic millions of shares	108	106	107	107	108	105
Weighted average shares, diluted millions of shares	115	112	114	114	115	109

Fiscal years (REGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,194	2,886	3,106	2,730	2,488	3,118
Marketable securities	1,393	2,809	4,636	8,115	6,524	5,487
Marketable securities, non-current	3,136	6,838	6,592	5,397	8,900	10,261
Accounts receivable	3,112	6,037	5,329	5,667	6,212	5,741
Inventory	1,917	1,951	2,402	2,581	3,087	3,201
Prepaid and other current assets	161	332	411	387	349	475
Total current assets	9,779	14,015	15,884	19,479	18,661	18,022
Property and equipment, net	3,222	3,482	—	—	—	—
Right-of-use asset	—	—	71	78	217	246
Total assets	17,163	25,435	29,215	33,080	37,759	40,559
Accounts payable	476	564	589	607	790	939
Total current liabilities	2,697	3,933	3,141	3,423	3,944	4,368
Long-term debt	1,979	1,980	1,981	1,983	1,984	1,986
Lease liability, non-current	—	—	56	69	204	229
Total liabilities	6,138	6,666	6,551	7,107	8,406	9,302
Retained earnings	10,893	18,968	23,307	27,260	31,673	35,797
Total stockholders' equity	11,025	18,769	22,664	25,973	29,354	31,257
Total liabilities and equity	17,163	25,435	29,215	33,080	37,759	40,559

Fiscal years (REGN's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	3,513	8,075	4,338	3,954	4,413	4,505
Stock-based compensation	432	602	725	885	983	994
Depreciation and amortization	236	286	341	421	483	544
Net cash from operating activities	2,618	7,081	5,015	4,594	4,421	4,979
Net cash from investing activities	(71)	(5,385)	(3,785)	(3,185)	(2,468)	(629)
Proceeds from issuing common stock	2,575	1,672	1,520	1,146	1,465	636
Share repurchases	5,847	1,645	2,083	2,235	2,603	3,439
Dividends paid	—	—	—	0	0	370
Proceeds from long-term debt	1,982	0	0	—	—	—
Net cash from financing activities	(1,971)	(1,006)	(1,009)	(1,790)	(2,201)	(3,715)
Net change in cash	577	691	221	(382)	(249)	635

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026
Vertex Pharmaceuticals	4,979	3,441	643*	253.5M	Q3 FY26 10-QSep 30, 2026
Pfizer	1,824	16,583	5,375*	5.7B	Q3 FY26 10-QSep 27, 2026
INSMED	397	524	(36)*	219.4M	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.